Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 18 Jul 2017

German Biotech Strikes License Deal with Japanese Dermatology Firm

4SC has granted an exclusive worldwide license to the Japanese dermatology firm Maruho on a class of compounds against the Kv1.3 ion channel. Under the agreement, 4SC could receive up to €105M in upfront and milestone payments plus royalties on future sales. The deal is part of the German company’s strategy to out license non-core […]

July 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Best in Biotech 18 Jul 2017

Is DNA the Future? The Best Biotech Talks of the Year

We’ve compiled our favorite talks of the year by some of the best leaders in the field about how biotech will change our lives in coming years. Biotech is rapidly advancing thanks to the huge improvements the technology to both read and write DNA has experienced in the past years. While devices become smaller and […]

July 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 17 Jul 2017

Israeli Biotech Partners with German Chem Giant to Develop Non-GMO Herbicide Resistance

Kaiima and BASF have partnered to develop crops with new herbicide resistance traits using non-GMO genetic engineering technology. Kaiima Bio Agritech works on boosting crop performance by using the plant’s own DNA, without the need of introducing external genes. In order to leverage this technology, the company has partnered with the giant chemical company BASF to discover […]

July 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 15 Jul 2017

Speculative Biology in Art: How will Life Look like in the Future?

The first solo exhibition of Turkish artist Pinar Yoldas imagines a future where biology is shaped by climate change and plastic pollution. Last week in Amsterdam opened Carboniferous, a solo bioart exhibition by Pinar Yoldas focusing on speculative biology. This concept revolves around imagining how life will evolve according to predictions of how the planet’s future ecosystems […]

July 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

inflammatory disease imperial college london macrophage

News and Trends 12 Jul 2017

British Researchers “Calm Down” Macrophages to treat Inflammation

Imperial College London and Ergon Pharmaceuticals have a new enzyme target to treat inflammatory disease by reducing the activity of macrophages. Researchers at Imperial College London have developed a method to reprogram macrophages and reduce their inflammatory activity. The approach, published in Nature Communications, proved to reduce by more than half inflammation in the joints […]

July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

genetically modified mosquitoes Oxitec Netherlands

News and Trends 12 Jul 2017

Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release

Update (12/07/2017): France’s High Council for Biotechnology (HCB) has also backed the use, with caution, of genetically modified mosquitoes in France. Oxitec expects the report published by the HCB will help shape the policy to regulate the genetically engineered insects in France and eventually allow testing the technology in the French Caribbean. Originally published on 07/07/2017 A […]

July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Erytech pharma Queens university red blood cells

News and Trends 12 Jul 2017

French Biotech and Canadian University to treat Rare Disease with Red Blood Cells

Erytech Pharma has entered a partnership with Queen’s University to treat the rare disease arginase-1 deficiency using engineered red blood cells. Erytech, based in Lyon, is known for its unique technology for drug delivery. Its most advanced program, in Phase IIb for metastatic pancreatic cancer, employs red blood cells engineered to produce the enzyme L-asparaginase, which depletes […]

July 12, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 11 Jul 2017

Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing

Blueprint Genetics has raised €14M to boost its genetic diagnostics platform, using artificial intelligence to interpret next-generation sequencing data. Based in Helsinki, Finland, Blueprint Genetics is a startup that addresses the main bottleneck of genetic testing through next-generation sequencing (NGS), the interpretation of massive volumes of data, with the aid of artificial intelligence (AI). Its […]

July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Microbiome Diagnostics Partners Enterome Nestle e1517266503234

News and Trends 11 Jul 2017

Enterome and Nestle Launch a New Microbiome Diagnostics Company

Microbiome Diagnostics Partners will develop diagnostics tests with Enterome’s microbiome platform IP and a €20M investment from Nestlé. Nestlé Health Science and Enterome have created Microbiome Diagnostics Partners (MDP) as a joint venture split 50% between both parties. Nestlé has invested €20M for its stake in the new company as well as the exclusive option to commercialize […]

July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat the motor complications of standard levodopa therapy. The Phase II trial will enroll 165 patients across the UK, Germany, France, Austria, Spain and Italy to monitor the effects of Prexton’s foliglurax. The company is looking for patients that have been treated […]

July 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq

Zealand Pharma, known for its partnership with Sanofi to boost the insulin blockbuster Lantus, is aiming high in an IPO on the US Nasdaq. Zealand Pharma has announced it has already filed for an IPO at the Nasdaq Global Select Market, an exclusive listing for large cap companies. Currently listed on the Nasdaq Copenhagen, Zealand Pharma […]

July 10, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the start of a Phase III program that seeks to recruit 250 patients to test its RNAi drug fitusiran in patients with both hemophilia A and […]

July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

German Biotech Strikes License Deal with Japanese Dermatology Firm

Is DNA the Future? The Best Biotech Talks of the Year

Israeli Biotech Partners with German Chem Giant to Develop Non-GMO Herbicide Resistance

Speculative Biology in Art: How will Life Look like in the Future?

British Researchers “Calm Down” Macrophages to treat Inflammation

Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release

French Biotech and Canadian University to treat Rare Disease with Red Blood Cells

Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing

Enterome and Nestle Launch a New Microbiome Diagnostics Company

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s

Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!